The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors

Dysregulation of phosphoinositide 3-kinase (PI3K) signaling is highly implicated in tumorigenesis, disease progression, and the development of resistance to the current standard of care treatments in breast cancer patients. This review discusses the role of PI3K pathway in breast cancer and evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhizhu, Richmond, Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139556/
https://www.ncbi.nlm.nih.gov/pubmed/34026830
http://dx.doi.org/10.3389/fmolb.2021.648663
_version_ 1783696034516434944
author Zhang, Zhizhu
Richmond, Ann
author_facet Zhang, Zhizhu
Richmond, Ann
author_sort Zhang, Zhizhu
collection PubMed
description Dysregulation of phosphoinositide 3-kinase (PI3K) signaling is highly implicated in tumorigenesis, disease progression, and the development of resistance to the current standard of care treatments in breast cancer patients. This review discusses the role of PI3K pathway in breast cancer and evaluates the clinical development of PI3K inhibitors in both early and metastatic breast cancer settings. Further, this review examines the evidence for the potential synergistic benefit for the combination treatment of PI3K inhibition and immunotherapy in breast cancer treatment.
format Online
Article
Text
id pubmed-8139556
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81395562021-05-22 The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors Zhang, Zhizhu Richmond, Ann Front Mol Biosci Molecular Biosciences Dysregulation of phosphoinositide 3-kinase (PI3K) signaling is highly implicated in tumorigenesis, disease progression, and the development of resistance to the current standard of care treatments in breast cancer patients. This review discusses the role of PI3K pathway in breast cancer and evaluates the clinical development of PI3K inhibitors in both early and metastatic breast cancer settings. Further, this review examines the evidence for the potential synergistic benefit for the combination treatment of PI3K inhibition and immunotherapy in breast cancer treatment. Frontiers Media S.A. 2021-05-07 /pmc/articles/PMC8139556/ /pubmed/34026830 http://dx.doi.org/10.3389/fmolb.2021.648663 Text en Copyright © 2021 Zhang and Richmond. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Zhang, Zhizhu
Richmond, Ann
The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors
title The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors
title_full The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors
title_fullStr The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors
title_full_unstemmed The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors
title_short The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors
title_sort role of pi3k inhibition in the treatment of breast cancer, alone or combined with immune checkpoint inhibitors
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139556/
https://www.ncbi.nlm.nih.gov/pubmed/34026830
http://dx.doi.org/10.3389/fmolb.2021.648663
work_keys_str_mv AT zhangzhizhu theroleofpi3kinhibitioninthetreatmentofbreastcanceraloneorcombinedwithimmunecheckpointinhibitors
AT richmondann theroleofpi3kinhibitioninthetreatmentofbreastcanceraloneorcombinedwithimmunecheckpointinhibitors
AT zhangzhizhu roleofpi3kinhibitioninthetreatmentofbreastcanceraloneorcombinedwithimmunecheckpointinhibitors
AT richmondann roleofpi3kinhibitioninthetreatmentofbreastcanceraloneorcombinedwithimmunecheckpointinhibitors

Ejemplares similares